Leorah Ross

2.3k total citations · 1 hit paper
23 papers, 1.6k citations indexed

About

Leorah Ross is a scholar working on Physiology, Organic Chemistry and Molecular Biology. According to data from OpenAlex, Leorah Ross has authored 23 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Physiology, 11 papers in Organic Chemistry and 10 papers in Molecular Biology. Recurrent topics in Leorah Ross's work include Lysosomal Storage Disorders Research (19 papers), Carbohydrate Chemistry and Synthesis (11 papers) and Glycosylation and Glycoproteins Research (7 papers). Leorah Ross is often cited by papers focused on Lysosomal Storage Disorders Research (19 papers), Carbohydrate Chemistry and Synthesis (11 papers) and Glycosylation and Glycoproteins Research (7 papers). Leorah Ross collaborates with scholars based in United States, Russia and Argentina. Leorah Ross's co-authors include George D. Yancopoulos, Ella Ioffe, John S. Rudge, Nicole L. Glazer, Susan D. Croll, Gavin Thurston, Donald M. McDonald, Jocelyn Holash, Annette T. Byrne and Limin Hu and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Medicine.

In The Last Decade

Leorah Ross

21 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Angiopoietin-1 protects the adult vasculature against plasma leakage

2000 1.1k citations Gavin Thurston, John S. Rudge et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Leorah Ross United States	7	931	285	266	253	227	23	1.6k
Laura A. Maile United States	28	874 0.9×	200 0.7×	307 1.2×	120 0.5×	131 0.6×	48	1.5k
Noël Lamandé France	21	865 0.9×	136 0.5×	296 1.1×	124 0.5×	394 1.7×	38	1.6k
Peter W. Hewett United Kingdom	24	988 1.1×	143 0.5×	231 0.9×	302 1.2×	159 0.7×	42	2.0k
R. Scott Pearsall United States	25	1.4k 1.5×	296 1.0×	180 0.7×	300 1.2×	186 0.8×	62	2.4k
Valter Agosti Italy	27	1.2k 1.3×	109 0.4×	264 1.0×	232 0.9×	254 1.1×	43	2.2k
Hsuan-Ying Huang Taiwan	30	1.2k 1.3×	173 0.6×	434 1.6×	700 2.8×	91 0.4×	55	2.4k
Maija Bry Finland	13	882 0.9×	142 0.5×	232 0.9×	496 2.0×	200 0.9×	16	1.5k
Ghislaine Escourrou France	19	800 0.9×	310 1.1×	673 2.5×	836 3.3×	154 0.7×	49	2.3k
Kevin Krasinski United States	13	808 0.9×	170 0.6×	301 1.1×	211 0.8×	169 0.7×	13	1.4k
Koshi Fujikawa Japan	16	854 0.9×	59 0.2×	235 0.9×	290 1.1×	185 0.8×	41	1.7k

Countries citing papers authored by Leorah Ross

Since Specialization

Citations

This map shows the geographic impact of Leorah Ross's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leorah Ross with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leorah Ross more than expected).

Fields of papers citing papers by Leorah Ross

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leorah Ross. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leorah Ross. The network helps show where Leorah Ross may publish in the future.

Co-authorship network of co-authors of Leorah Ross

This figure shows the co-authorship network connecting the top 25 collaborators of Leorah Ross. A scholar is included among the top collaborators of Leorah Ross based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leorah Ross. Leorah Ross is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Keutzer, Joan, et al.. (2022). Use of Identical INN “Imiglucerase” for Different Drug Products: Impact Analysis of Adverse Events in a Proprietary Global Safety Database. Drug Safety. 45(2). 127–136.

Ruskin, Jeremy N., Catherine Ortemann‐Renon, Jérôme Msihid, et al.. (2020). How a concentration-effect analysis of data from the eliglustat thorough electrocardiographic study was used to support dosing recommendations. Molecular Genetics and Metabolism. 131(1-2). 211–218. 6 indexed citations

Cox, Gerald F., et al.. (2020). Effects of paroxetine, ketoconazole, and rifampin on the metabolism of eliglustat, an oral substrate reduction therapy for Gaucher disease type 1. Molecular Genetics and Metabolism Reports. 22. 100552–100552. 6 indexed citations

Thibault, Nathan, Jennifer Ibrahim, Michel Peterschmitt, et al.. (2020). Effect of eliglustat on the pharmacokinetics of digoxin, metoprolol, and oral contraceptives and absorption of eliglustat when coadministered with acid-reducing agents. Molecular Genetics and Metabolism. 129(4). 278–285. 5 indexed citations

Cox, Timothy M., Guillermo Drelichman, Manisha Balwani, et al.. (2015). Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial. The Lancet. 385(9985). 2355–2362. 118 indexed citations

Lau, Heather, Jennifer Ibrahim, Michel Peterschmitt, & Leorah Ross. (2015). Tremor and peripheral neuropathy are infrequent and non-serious events in Gaucher type 1 patients treated with eliglustat. Molecular Genetics and Metabolism. 114(2). S69–S70. 4 indexed citations

Mistry, Pramod K., Dominick Amato, Majed Dasouki, et al.. (2015). ENGAGE — A phase 3, randomized, double-blind, placebo-controlled, multi-center study to investigate the efficacy and safety of eliglustat in adults with Gaucher disease type 1: Results after 18months. Molecular Genetics and Metabolism. 114(2). S81–S82. 8 indexed citations

Cox, Timothy M., Guillermo Drelichman, Manisha Balwani, et al.. (2015). ENCORE, a randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in Gaucher disease type 1 patients stabilized on enzyme replacement therapy: 24-month results. Molecular Genetics and Metabolism. 114(2). S33–S34. 8 indexed citations

Lukina, Elena, Nora Watman, Marta Dragosky, et al.. (2014). Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatment. Blood Cells Molecules and Diseases. 53(4). 274–276. 61 indexed citations

10.

Ross, Leorah, Ana Cristina Puga, Gerald F. Cox, et al.. (2014). Eliglustat safety profile based on a pooled analysis of data from four trials in Gaucher disease type I. Molecular Genetics and Metabolism. 111(2). S90–S90. 4 indexed citations

11.

Cox, Timothy M., Guillermo Drelichman, Manisha Balwani, et al.. (2014). ENCORE: A randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in Gaucher disease type 1 patients on enzyme replacement therapy who have reached therapeutic goals. Molecular Genetics and Metabolism. 111(2). S33–S33. 1 indexed citations

12.

Rosenbloom, Barry E., Timothy M. Cox, Guillermo Drelichman, et al.. (2014). Encore - a Randomized, Controlled, Open-Label Non-Inferiority Study Comparing Eliglustat to Imiglucerase in Gaucher Disease Type 1 Patients Stabilized on Enzyme Replacement Therapy: 24-Month Results. Blood. 124(21). 1406–1406. 2 indexed citations

13.

Amato, Dominick, Majed Dasouki, Seymour Packman, et al.. (2014). Engage - a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Investigate the Efficacy and Safety of Eliglustat in Adults with Gaucher Disease Type 1: Results after 18 Months. Blood. 124(21). 2732–2732. 4 indexed citations

14.

Balwani, Manisha, Timothy M. Cox, Guillermo Drelichman, et al.. (2013). Encore: A Randomized, Controlled, Open-Label Non-Inferiority Study Comparing Eliglustat To Imiglucerase In Gaucher Disease Type 1 Patients On Enzyme Replacement Therapy Who Have Reached Therapeutic Goals. Blood. 122(21). 3468–3468. 5 indexed citations

15.

Peterschmitt, Michel, Elena Lukina, Nora Watman, et al.. (2012). Eliglustat, an Investigational Oral Therapy for Gaucher Disease Type 1: Phase 2 Results After 4 Years of Treatment. Blood. 120(21). 1038–1038. 2 indexed citations

16.

Peterschmitt, Michel, Elena Lukina, Nora Watman, et al.. (2012). Eliglustat, an Investigational Oral Therapy for Gaucher Disease Type 1 (GD1): Updated Phase 2 Results. Molecular Genetics and Metabolism. 105(2). S52–S52. 1 indexed citations

17.

Peterschmitt, Michel, Elena Lukina, Nora Watman, et al.. (2011). Eliglustat, An Investigational Oral Therapy for Gaucher Disease Type 1: Phase 2 Results After 3 Years. Blood. 118(21). 1104–1104. 2 indexed citations

18.

Peterschmitt, Michel, Ravi S. Kamath, Elena Lukina, et al.. (2011). Improvements in Skeletal Manifestations in Gaucher Disease Type 1 Patients After 3 Years of Treatment with Oral Eliglustat During a Phase 2 Trial,. Blood. 118(21). 3216–3216. 1 indexed citations

19.

Byrne, Annette T., Leorah Ross, Mikiye Nakanishi, et al.. (2003). Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model.. PubMed. 9(15). 5721–8. 248 indexed citations

20.

Thurston, Gavin, John S. Rudge, Ella Ioffe, et al.. (2000). Angiopoietin-1 protects the adult vasculature against plasma leakage. Nature Medicine. 6(4). 460–463. 1055 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact